LOREM THERAPEUTICS

Lorem Therapeutics is focusing on development early stage therapeutics in the phase between initial drug discovery and when a treatment begins review by the FDA for status as an Investigational New Drug. The company will use the funding “to accelerate and enhance our drug discovery efforts around critical cancer indications,” Slusher said in a statement.

#SimilarOrganizations #Financial #More

LOREM THERAPEUTICS

Industry:
Biotechnology Pharmaceutical Therapeutics

Address:
Baltimore, Maryland, United States

Country:
United States

Status:
Active

Total Funding:
0


Similar Organizations

shifa-biomedical-logo

Shifa Biomedical

Shifa Biomedical is a drug discovery company that develops drugs for the treatment of cardiovascular disease.

Investors List

ip-group-plc_image

IP Group

IP Group investment in Seed Round - Lorem Therapeutics

johns-hopkins-technology-ventures_image

Johns Hopkins Technology Ventures

Johns Hopkins Technology Ventures investment in Seed Round - Lorem Therapeutics

More informations about "Lorem Therapeutics"

Lorem Therapeutics - PitchBook

Lorem Therapeutics General Information Description. Operator of a drug discovery company intended to conduct research for cancer treatment. The company's platform focuses on the …See details»

Johns Hopkins-IP Group Collaboration Funds Cancer …

May 15, 2018 The Johns Hopkins University announces that IP Group has funded the creation of Lorem Therapeutics as part of an ongoing collaboration between the university and the intellectual property commercialization …See details»

Lorem Therapeutics - Funding, Financials, Valuation & Investors

Lorem Therapeutics has raised 1 round. This was a Seed round raised on May 14, 2018. Lorem Therapeutics is funded by 2 investors. IP Group and Johns Hopkins Technology Ventures are …See details»

Lorem Therapeutics - Products, Competitors, Financials, Employees ...

May 16, 2018 IP Group fills Lorem’s coffers Lorem Therapeutics has become the first Johns Hopkins spinout to secure funding through the institution’s partnership with IP Group. Author: …See details»

Lorem_Therapeutics - Johns Hopkins Drug Discovery

Lorem_Therapeutics. Home > Newcos Founded > Lorem_Therapeutics. Johns Hopkins Drug Discovery Transforming academic translational research at Johns Hopkins. Since 2009, the …See details»

Johns Hopkins startup gets funding from company turning …

May 15, 2018 A company that works to turn intellectual property into businesses is backing a new Johns Hopkins startup developing therapeutics to treat cancer. IP Group, which works …See details»

Lorem Therapeutics - Crunchbase

Lorem Therapeutics, Envoy Therapeutics, and Shifa Biomedical are focused on drug discovery and the development of innovative drugs for specific medical conditions. They are associated …See details»

Lorem Therapeutics - CB Insights

May 15, 2018 See Lorem Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on Lorem Therapeutics's post-money valuation and revenue. …See details»

Lorem Pharmaceuticals Inc - Company Profile and News

Lorem Pharmaceuticals Inc Lorem Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company focuses on developing early-stage therapeutics for the treatment of cancer …See details»

n-Lorem Foundation Partners with Argonaut to Manufacture ASO …

Feb 2, 2022 Argonaut to support n-Lorem’s expanding need for manufacturing of ASO therapeutics for nano-rare patients SAN DIEGO, Calif., February 02, 2022 (Business Wire) — …See details»

Johns Hopkins-IP Group Collaboration Funds Cancer Therapeutic …

The Johns Hopkins University announces that IP Group has funded the creation of Lorem Therapeutics as part of an ongoing collaboration between the university and the intellectual …See details»

GondolaBio and n-Lorem Foundation Partner to Advance Novel …

Dec 17, 2024 n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental …See details»

Cytori, Lorem Vascular To Commercialize Cell-Based Therapies

AsianScientist (Nov. 21, 2013) – Cytori Therapeutics and Lorem Vascular have announced a partnership to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes …See details»

Pioneering the Next Generation of ALS Therapeutics: Announcing …

22 hours ago Three research consortia have been awarded Target ALS funding this April to develop next-generation gene therapies for ALS through our latest grant initiative, Consortia …See details»

n-Lorem Foundation (n-Lorem Foundation) - 药物管线_专利_临床 …

To date, n-Lorem received over 300 applications for treatment with more than 140 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman …See details»

Lorem Vascular Licenses Cytori Cell Therapy for Asia-Pacific in Up …

Nov 5, 2013 Lorem Vascular also agreed to pay Cytori $24 million for 8 million shares of Cytori common stock at $3 per share—with $12 million to be paid within seven days, and another …See details»

N=1 Collaborative: advancing customized nucleic acid therapies …

22 hours ago Several organizations—including the Dutch Center for RNA therapeutics, the n-Lorem Foundation, ... non-profit organization, N1C serves as an independent and neutral …See details»

Lorem Vascular

Our flagship product is the market-leading Celution System® developed by Cytori Therapeutics, Inc. (U.S.A.). The Celution System® is a closed and sterile cell separation system that isolates …See details»

Lorem Therapeutics - Updates, News, Events, Signals & Triggers

Lorem Tx is a drug discovery company translating innovative drugs from Johns Hopkins University.See details»

N-Lorem, Gondolabio to advance ASO treatment for rare diseases

Jan 8, 2025 N-Lorem Foundation and Gondolabio are teaming up ... we have industrialized the treatment of nano-rare patients and created an organization capable of scaling up to meet a …See details»

linkstock.net © 2022. All rights reserved